Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • Cefodizime: Broad Spectrum Third-Generation Cephalosporin...

    2026-01-20

    Cefodizime: Broad Spectrum Third-Generation Cephalosporin for Infectious Disease Research

    Executive Summary: Cefodizime is a third-generation cephalosporin antibiotic recognized for its broad antimicrobial activity against Gram-positive and Gram-negative bacteria (Barradell & Brogden, 1992, PubMed). It demonstrates low nephrotoxicity and high tolerability in preclinical and clinical studies (ibid). Cefodizime exerts its effect by inhibiting bacterial cell wall synthesis, resulting in bactericidal activity. Its immunomodulatory properties may enhance host defense mechanisms in infection models. When used according to storage and handling recommendations, Cefodizime maintains stability and efficacy in laboratory settings (APExBIO).

    Biological Rationale

    Cefodizime is classified as a third-generation cephalosporin antibiotic. It targets a broad range of bacterial pathogens, including strains relevant to respiratory and urinary tract infections (Barradell & Brogden, 1992). The compound is particularly suited for research into infectious diseases where both Gram-positive and Gram-negative organisms are implicated. Cefodizime's low potential for nephrotoxicity makes it suitable for experiments requiring repeated or high-dose administration, reducing confounding variables related to kidney impairment (APExBIO).

    Mechanism of Action of Cefodizime

    Cefodizime acts by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting the final stages of peptidoglycan synthesis (Barradell & Brogden, 1992). This results in weakened cell walls, osmotic instability, and ultimately cell lysis and death. The drug is stable against many beta-lactamases, which confers activity against beta-lactamase-producing strains (ibid). Its action is concentration-dependent and primarily bactericidal. Sub-inhibitory concentrations have also been reported to modulate certain immune cell functions, such as enhancing neutrophil activity (ibid; see also Cefodizime in Translational Infectious Disease Research, which expands on the immunomodulatory effects).

    Evidence & Benchmarks

    • Cefodizime inhibits ≥90% of Enterobacteriaceae strains at ≤8 mg/L in vitro (Barradell & Brogden, 1992, PubMed).
    • Effective against common Gram-negative (e.g., Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis) and Gram-positive species (e.g., Streptococcus pneumoniae, Staphylococcus aureus) (ibid).
    • Clinical cure rates of 80–100% for upper/lower respiratory and urinary tract infections at intravenous dosages of 1–4 g/day for 7–10 days (ibid).
    • Single 1–2 g doses are highly effective (72–88% cure) for lower urinary tract infections (ibid).
    • Displays low nephrotoxicity compared to other cephalosporins, as demonstrated in renal impairment studies (ibid).
    • Immunomodulatory effects observed: increased neutrophil and macrophage activity in animal models (Barradell & Brogden, 1992, Table 6).
    • Elimination half-life is longer than many cephalosporins (~3.5–4 hours in adults), allowing for once or twice daily dosing (ibid).
    • Protein binding: 70–80% in human plasma, supporting sustained serum concentrations (ibid).

    Applications, Limits & Misconceptions

    Cefodizime is widely used in microbiology and infectious disease research for modeling infections caused by both Gram-positive and Gram-negative pathogens. Its use is well-documented in respiratory and urinary tract infection models, and it is also of interest for studies on immune response modulation (Cefodizime: Advanced Insights; this article updates the pharmacokinetic data and practical application details). Unlike some cephalosporins, Cefodizime is suitable for studies requiring preserved renal function due to its low nephrotoxicity profile.

    Common Pitfalls or Misconceptions

    • Not suited for long-term solution storage: Cefodizime solutions degrade and should be prepared fresh; solid should be stored at -20°C (APExBIO).
    • Ineffective against Pseudomonas aeruginosa and certain Enterococcus spp.: These species are intrinsically resistant (Barradell & Brogden, 1992).
    • Not a substitute for carbapenems in multi-drug resistant infections: Its spectrum does not cover all resistant Gram-negative bacteria.
    • Oral bioavailability is negligible: Cefodizime is for parenteral (IV or IM) use only (ibid).
    • Immunomodulatory effects are context-dependent: Enhanced immune cell activity is not universal across all infection models (see also Cefodizime: A Broad Spectrum Antibiotic for Next-Generation Research, which discusses model-dependent immunomodulation; this article clarifies underlying mechanisms and boundary conditions).

    Workflow Integration & Parameters

    Cefodizime is supplied as a solid by APExBIO (Cefodizime BA1050), to be stored at -20°C. It should be reconstituted in sterile water or suitable buffer immediately prior to use. Solutions should not be stored long-term; use within hours of preparation is recommended (APExBIO). Standard working concentrations for in vitro assays range from 0.5–16 mg/L, depending on the bacterial strain and experimental endpoint. For animal studies, typical dosing is 1–4 g/day IV or IM, in accordance with published pharmacokinetic and efficacy data (Barradell & Brogden, 1992). Shipping is performed on blue ice to ensure compound stability in transit. The BA1050 kit provides batch-specific documentation for reproducibility.

    For further guidance on experimental design and troubleshooting, the article Cefodizime: Broad Spectrum Antibiotic for Infectious Disease Models offers actionable protocols and comparative insights; the current article extends this by providing updated storage and integration recommendations.

    Conclusion & Outlook

    Cefodizime remains a robust tool for microbiology and infectious disease research, offering broad-spectrum activity, low nephrotoxicity, and immunomodulatory potential. Its well-characterized pharmacokinetics and tolerability profile enable reliable modeling of bacterial infections and host responses. Ongoing research aims to further clarify its immunological effects and expand its application in translational models. For detailed product specifications and ordering, consult the APExBIO Cefodizime BA1050 product page.